North America Liver Disease Treatment Market by Treatment Type (Antiviral Drugs, Immunosuppressants, Vaccines, Immunoglobulins, Corticosteroids, Targeted Therapy, and Chemotherapy) and Disease Type (Hepatitis, Autoimmune Diseases, Non-Alcoholic Fatty Liver Disease, Cancer, Genetic Disorders, and Others): Opportunity Analysis and Industry Forecast, 2020–2027
The North America liver disease treatment market accounted for $6,970 million in 2019, and is expected to reach $8,318 million by 2027, registering a CAGR of 5.2% from 2020 to 2027.
Medical care given to a patient suffering from liver diseases is termed as liver disease treatment. Furthermore, the treatment includes use of various drugs for different types of liver conditions. For instance, hepatitis B is a liver disease caused by a virus called hepatitis B virus (HBV). This condition is treated using antiviral drugs and can also be prevented by use of vaccines. Furthermore, other drugs that are used in treatment of hepatitis include immunoglobulin. Similarly, liver cancer is treated by using chemotherapy drugs and targeted therapy. In addition, some autoimmune liver related disorders are treated with the use of corticosteroids.
Furthermore, liver associated conditions also require liver transplant in many cases, where immunosuppressant drugs are used to prevent organ rejection. Thus, there are various types of liver treatments offered in the market such as anti-viral drugs, immunosuppressant drugs, vaccines, immunoglobulin, corticosteroid, targeted therapy, and chemotherapy drugs. In addition, these products are used to cure a range of liver diseases, which include hepatitis, autoimmune diseases, non-alcoholic fatty liver, and genetic disorders.
The major factors that contribute toward growth of the North America liver disease treatment market include increase in alcohol consumption & use of illegal drugs and rise in prevalence of liver disease. Furthermore, it is also a primary cause for worsening of various liver conditions, which require treatment. For instance, consumption of large quantity of alcohol can lead to liver condition called alcoholic hepatitis, which, in turn, leads to liver inflammation that requires treatment. Furthermore, factors such as surge in geriatric population and increase in government and non-government awareness programs also boost growth of the North America liver disease treatment market. For instance, older patients who acquire hepatitis C infection are more likely to develop cirrhosis in the coming years, owing to accelerated fibrosis rate and decreased immunity.
However, stringent approval process related to drugs and resistance to antiviral drugs used in treatment of hepatitis B and hepatitis C of drugs restrict growth of the North America liver disease treatment market. For instance, approval processes require a huge capital investment. Moreover, any new drug manufacturing company that tries to enter into the market is bound to abide by these regulations. Therefore, these procedures are time consuming, which extends the time for their approval and commercialization and restricts growth of the market. Conversely, presence of strong pipeline products offer a lucrative opportunity for the market growth.
The North America liver disease treatment market is segmented on the basis of treatment type, disease type, and country to provide a detailed assessment of the market. By treatment type, the market is divided into antiviral drugs, immunosuppressants, vaccines, immunoglobulins, corticosteroids, targeted therapy, and chemotherapy. By disease type, it is divided into hepatitis, autoimmune diseases, non-alcoholic fatty liver disease (NAFLD), cancer, genetic disorders and others. By country, it is classified into the U.S., Canada, and Mexico.Major players operating in the market include, Astellas Pharma Inc., Mylan N.V., AbbVie Inc., Merck & Co., Inc. (Merck Sharp & Dohme Corp.), Eli Lilly and Company, Pfizer Inc., Dynavax Technologies, Gilead Sciences, Inc., Bristol Myers Squibb, and Emergent BioSolutions (Cangene bioPharma).
KEY BENEFITS FOR STAKEHOLDERS • This report entails a detailed quantitative analysis along with the current global North America liver disease treatment market trends from 2019 to 2027 to identify the prevailing opportunities along with the strategic assessments.
• The market size and estimations are based on a comprehensive analysis of key developments in the industry.
• A qualitative analysis based on innovative products facilitates strategic business planning.
• The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market
Key Market Segments • By Treatment Type
o Antiviral Drugs
o Targeted Therapy
• By Disease Type
o Autoimmune Diseases
o Ischemic Stroke
• By Country
• List of key players profiled in the report:
• Astellas Pharma Inc.
• AbbVie Inc.
• Merck & Co., Inc. (Merck Sharp & Dohme Corp.)
• Eli Lilly and Company
• Dynavax Technologies
• Pfizer Inc.
• Gilead Sciences, Inc.,
• Bristol Myers Squibb
• Emergent BioSolutions (Cangene bioPharma)
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request) • Sanofi
• F. Hoffmann-La Roche AG
• Novartis AG
Our reports have been used by over 10K customers, including:
Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) - Drugs in Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Non Alcoholic Fatty Liver Disease - Drugs in Development, 2021, provides an overview of the Non Alcoholic Fatty Liver Disease (Gastrointestinal)...
Best foot forward: Revenue will likely rise as more healthcare providers stress the importance of preventive care Abstract Podiatrists in the US Over the five years to 2019, the Podiatrists industry has stepped in the right direction. Revenue growth has been supported by the aging US population and...
Stretch goals: Rising disposable incomes and an aging population will drive revenue growth Abstract Physical Therapists in the US Over the five years to 2019, the role of physical therapy in promoting health and wellness has increased, benefiting this industry. As the number of individuals aged 50 and...
The global immunofluorescence assays market is projected to reach USD 3.5 billion by 2026 from USD 2.6 billion in 2021, at a CAGR of 6.0% during the forecast period. The growth in this market is primarily attributed to the increasing prevalence of chronic diseases and rising R&D spending & healthcare expenditure. Emerging markets are expected...
The North America organoids market is expected to reach US$ 1,406.47 million by 2027 from US$ 291.39 million in 2019. The market is anticipated to grow at a CAGR of 21.7% from 2020 to 2027. Growth of the North America organoids market is attributed to emergence of three-dimensional (3D) organoids and rise in investments in research. However,...
The global organoids market is expected to reach US$ 3,420.40 million by 2027 from US$ 689.47 million in 2019. The market is estimated to grow at a CAGR of 22.1% from 2020 to 2027. Increasing demand for tumor modelling and biobanking, rising adoption of personalized drugs, and growing focus on developing alternatives for animal testing...
An organ-on-a-chip is a microfluidic cell culture device that contains continuously perfused chambers. This chip develops a narrow channel for the blood and airflow in organs, such as the lung, gut, liver, heart, and other organs. Such devices produce multiple levels of tissue and organ functionalities, which are not feasible using conventional...
Healthy future: Despite the mounting likelihood of new regulation, industry revenue will likely grow Abstract Cryogenic Biobanking Services Since the landmark scientific achievement of human genome sequencing in 2003, the Cryogenic Biobanking Services industry is increasingly viewed as the link between...
Abstract Fleet Telematics Systems Procurement in the US This report is intended to assist buyers of fleet telematics systems. Fleet telematics systems are used to monitor, map and track vehicle fleets in the field. Digital maps and Global Positioning System (GPS) technology allow for real-time visualization...
Anatomic pathology market to register a CAGR of 7.1% from 2020 to 2025. The global anatomic pathology market size is projected to reach a value of USD 46.8 billion by 2025 from USD 33.3 billion in 2020, at a CAGR of 7.1% during the forecast period. The growth in this market is attributed to the high incidence of cancer...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.